Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases.

Barnes PJ, Karin M.

N Engl J Med. 1997 Apr 10;336(15):1066-71. Review. No abstract available.

PMID:
9091804
2.

Nuclear factor-kappa B.

Barnes PJ.

Int J Biochem Cell Biol. 1997 Jun;29(6):867-70. Review.

PMID:
9304801
3.

NF-kappaB signaling: pros and cons of altering NF-kappaB as a therapeutic approach.

Egan LJ, Toruner M.

Ann N Y Acad Sci. 2006 Aug;1072:114-22. Review.

PMID:
17057194
4.

Nuclear factor-kappa B: from clone to clinic.

Ahn KS, Sethi G, Aggarwal BB.

Curr Mol Med. 2007 Nov;7(7):619-37. Review.

PMID:
18045141
5.

Abnormal activation of transcription factor NF-kappaB involved in steroid resistance in chronic inflammatory bowel disease.

Bantel H, Domschke W, Schulze-Osthoff K, Kaskas B, Gregor M.

Am J Gastroenterol. 2000 Jul;95(7):1845-6. No abstract available.

PMID:
10926007
6.

Direct inhibition of NF-kappa B blocks bone erosion associated with inflammatory arthritis.

Clohisy JC, Roy BC, Biondo C, Frazier E, Willis D, Teitelbaum SL, Abu-Amer Y.

J Immunol. 2003 Nov 15;171(10):5547-53.

7.

Small-molecule inhibitors of NF-kappaB for the treatment of inflammatory joint disease.

Roshak AK, Callahan JF, Blake SM.

Curr Opin Pharmacol. 2002 Jun;2(3):316-21. Review.

PMID:
12020477
8.

NF-kappaB as a therapeutic target in chronic inflammation: recent advances.

Makarov SS.

Mol Med Today. 2000 Nov;6(11):441-8. Review.

PMID:
11074370
9.

Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-kappaB-dependent mechanism.

Vanden Berghe W, Francesconi E, De Bosscher K, Resche-Rigon M, Haegeman G.

Mol Pharmacol. 1999 Oct;56(4):797-806.

10.

Role of the NF-kappaB pathway in the pathogenesis of human disease states.

Yamamoto Y, Gaynor RB.

Curr Mol Med. 2001 Jul;1(3):287-96. Review.

PMID:
11899077
11.
12.

Roles of NF-kappaB in health and disease: mechanisms and therapeutic potential.

Wong ET, Tergaonkar V.

Clin Sci (Lond). 2009 Mar;116(6):451-65. doi: 10.1042/CS20080502. Review.

PMID:
19200055
13.

A role for transcription factor NF-kappa B in intestinal inflammation.

Schottelius AJ, Baldwin AS Jr.

Int J Colorectal Dis. 1999 Feb;14(1):18-28. Review.

PMID:
10207726
14.

Nuclear factor kappa B: important transcription factor and therapeutic target.

Lee JI, Burckart GJ.

J Clin Pharmacol. 1998 Nov;38(11):981-93. Review.

PMID:
9824778
15.

From willow bark to peptides: the ever widening spectrum of NF-kappaB inhibitors.

D'Acquisto F, Ianaro A.

Curr Opin Pharmacol. 2006 Aug;6(4):387-92. Epub 2006 Jun 14. Review.

PMID:
16781194
16.

[NF-kappa B and inflammatory intestinal diseases].

Nosti-Escanilla MP, Peña AS.

Rev Esp Enferm Dig. 1998 Feb;90(2):113-9. Review. Spanish.

PMID:
9580438
17.

[Inflammation, prelude to renal sclerosis: the importance of NF-kappa B].

Baud L, Fouqueray B, Bellocq A, Haymann JP, Peltier J.

J Soc Biol. 2002;196(4):269-73. Review. French.

PMID:
12645294
18.

[The Rel/NF-kappa-B transcription factors: complex role in cell regulation].

Bottex-Gauthier C, Pollet S, Favier A, Vidal DR.

Pathol Biol (Paris). 2002 Apr;50(3):204-11. Review. French.

PMID:
11980335
19.

Nuclear factor-kappa B in intestinal protection and destruction.

Spehlmann ME, Eckmann L.

Curr Opin Gastroenterol. 2009 Mar;25(2):92-9. doi: 10.1097/MOG.0b013e328324f857. Review.

PMID:
19528876
20.

NF-kappaB in inflammatory bowel disease.

Atreya I, Atreya R, Neurath MF.

J Intern Med. 2008 Jun;263(6):591-6. doi: 10.1111/j.1365-2796.2008.01953.x. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk